THERAPY DOSSIER · th-7b746684c30d

Pyruvate-enriched carrier solutions for hydroxyethyl starch 130/0.4 (HES130/0.4) resuscitation fluid: pyruvate saline (PS), and acetate Ringer's plus pyruvate-HES (SP), compared with acetate-HES (SA), normal saline-HES (SN) and normal saline (NS) carriers

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Burn
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29605028 ↗2018Reported benefit

Pyruvate as a novel carrier of hydroxyethyl starch 130/0.4 may protect kidney in rats subjected to severe burns.

RatBurnUnspecifiedSprague-DawleyMalen = 140 rats total, randomly allocated into 7 groups of n=20 ea…Intravenous infusionHES130/0.4 infused at 18.75 mL/kg over 12 h, at a 1:1 ratio…Fluid resuscitation initiated after severe burn injury

Model: Lethal severe burn model in rats, followed by fluid resuscitation and assessment of burn-induced acute kidney injury

Pyruvate-enriched HES130/0.4 (group SP) and pyruvate saline (group PS) provided better renal preservation than corresponding normal-saline-carrier groups; group SP was significantly superior to group PS in renal surface blood flow, cystatin-C, NGAL, kidney water content and Paller histology scores…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…